Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

2.020 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

February 26, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

These stocks are moving in today's pre-market session ↗

February 26, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert ↗

February 26, 2025

U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading.

Via Benzinga

Topics Stocks

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

February 26, 2025

Via Benzinga

Which stocks are moving after the closing bell on Tuesday? ↗

February 25, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD ↗

February 25, 2025

Enveric Biosciences secures a U.S. patent for non-hallucinogenic mescaline derivatives targeting addiction, ADHD and anxiety.

Via Benzinga

Topics Derivatives Intellectual Property

Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease ↗

February 04, 2025

Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis.

Via Benzinga

What's going on in today's session ↗

January 31, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Dow Edges Lower; Exxon Mobil Earnings Top Views ↗

January 31, 2025

Via Benzinga

Topics Stocks

Which stocks are gapping on Friday? ↗

January 31, 2025

The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings ↗

January 31, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

January 31, 2025

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

January 31, 2025

Via Benzinga

What's going on in today's after hours session ↗

January 30, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

January 29, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Here are the top movers in Wednesday's session. ↗

January 29, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 29, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 27, 2024

Via Benzinga

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results ↗

November 25, 2024

Via Benzinga

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗

November 19, 2024

Via Benzinga

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders ↗

November 18, 2024

Via Benzinga

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal ↗

November 12, 2024

Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M.

Via Benzinga

Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions ↗

November 04, 2024

Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy.

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 23, 2024

Via Benzinga

Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic ↗

October 15, 2024

Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 15, 2024

Via Benzinga

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies ↗

October 04, 2024

Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.

Via Benzinga

Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research ↗

September 25, 2024

Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being...

Via Benzinga

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024 ↗

August 12, 2024

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

Headline News about Enveric Biosciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today